Torthaí cuardaigh - Laurence Albigès

Beachtaigh na torthaí
  1. 1
    Nivolumab in renal cell carcinoma: latest evidence and clinical potential

    Nivolumab in renal cell carcinoma: latest evidence and clinical potential de réir Camille Mazza, Bernard Escudier, Laurence Albigès

    Foilsithe / Cruthaithe 2016
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma

    Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma de réir Elie Rassy, Ronan Flippot, Laurence Albigès

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer

    ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer de réir Karim Fizazi, Laurence Albigès, Yohann Loriot, Christophe Massard

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma

    Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma de réir Hassan Izzedine, Lisa Derosa, Gwénaël Le Teuff, Laurence Albigès, Bernard Escudier

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases

    Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases de réir Laurence Albigès, Fabrice André, Corinne Balleyguier, Gonzalo Gomez-Abuin, Agnès Chompret, Suzette Delaloge

    Foilsithe / Cruthaithe 2005
    Faigh an téacs iomlán Faigh an téacs iomlán
    Carta
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma

    TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma de réir Laurence Albigès, Philippe Barthélémy, Marine Gross‐Goupil, Sylvie Négrier, Michael N. Needle, Bernard Escudier

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma

    Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma de réir Laurence Albigès, Foucauld Chamming’s, Brigitte Duclos, M. Stern, Robert J. Motzer, Alain Ravaud, P. Camus

    Foilsithe / Cruthaithe 2012
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography

    Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography de réir Nathalie Lassau, Serge Koscielny, Laurence Albigès, L. Chami, Baya Benatsou, Mohamed Chébil, Alain Roche, Bernard Escudier

    Foilsithe / Cruthaithe 2010
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma

    Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma de réir Christophe Maritaz, David Combarel, Cécile Dalban, Louis Blondel, Sophie Broutin, Aurélien Marabelle, Laurence Albigès, Angélo Paci

    Foilsithe / Cruthaithe 2025
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events

    Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events de réir Viktor Grünwald, Martin H. Voss, Brian I. Rini, Thomas Powles, Laurence Albigès, Rachel H. Giles, Eric Jonasch

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

    Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients de réir Luc Cabel, Elika Loir, Gwénaëlle Gravis, Pernelle Lavaud, Christophe Massard, Laurence Albigès, Giulia Baciarello, Yohann Loriot, Karim Fizazi

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  12. 12
    Radiologic Heterogeneity in Responses to Anti–PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma

    Radiologic Heterogeneity in Responses to Anti–PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma de réir Guillermo de Velasco, Katherine M. Krajewski, Laurence Albigès, Mark M. Awad, Joaquim Bellmunt, F. Stephen Hodi, Toni K. Choueiri

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  13. 13
    ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma

    ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma de réir Thomas Powles, Laurence Albigès, Axel Bex, Viktor Grünwald, Camillo Porta, Giuseppe Procopio, Manuela Schmidinger, Cristina Suárez, Guillermo de Velasco

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  14. 14
    Who dies from prostate cancer?

    Who dies from prostate cancer? de réir Anna Patrikidou, Yohann Loriot, J-C Eymard, Laurence Albigès, Christophe Massard, E. Ileana, Mario Di Palma, Bernard Escudier, Karim Fizazi

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  15. 15
    Renal cell carcinoma

    Renal cell carcinoma de réir James J. Hsieh, Mark P. Purdue, Sabina Signoretti, Charles Swanton, Laurence Albigès, Manuela Schmidinger, Daniel Y.C. Heng, James Larkin, Vincenzo Ficarra

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  16. 16
    Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

    Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) de réir Yohann Loriot, Diletta Bianchini, E. Ileana, Shahneen Sandhu, Anna Patrikidou, Carmel Pezaro, Laurence Albigès, Gerhardt Attard, Karim Fizazi, Johann S. de Bono, Christophe Massard

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  17. 17
    Thermal Ablation Combined with Immune Checkpoint Blockers: A 10-Year Monocentric Experience

    Thermal Ablation Combined with Immune Checkpoint Blockers: A 10-Year Monocentric Experience de réir Baptiste Bonnet, Louis Tournier, Frédèric Deschamps, Steven Yevich, Aurélien Marabelle, Caroline Robert, Laurence Albigès, Benjamin Besse, V Bonnet, Thierry de Baère, Lambros Tselikas

    Foilsithe / Cruthaithe 2024
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  18. 18
    Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma

    Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma de réir Anthony Saroufim, Yosra Messai, Meriem Hasmim, Nathalie Rioux, Roberto Iacovelli, G. Verhoest, Karim Bensalah, J-J Patard, Laurence Albigès, Bruno Azzarone, Bernard Escudier, Salem Chouaı̈b

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  19. 19
    Chk1 as a new therapeutic target in triple-negative breast cancer

    Chk1 as a new therapeutic target in triple-negative breast cancer de réir Laurence Albigès, Aïcha Goubar, Véronique Scott, Cécile Vicier, Céline Lefèbvre, Samar Alsafadi, Frédéric Commo, Mahasti Saghatchian, Vladimir Lazar, Philippe Dessen, Suzette Delaloge, Fabrice André, Virginie Quidville

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  20. 20
    Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors

    Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors de réir Sarah C. Markt, Carlos Lago‐Hernandez, Rowan Miller, Brandon A. Mahal, Brandon Bernard, Laurence Albigès, Lindsay A. Frazier, Clair J. Beard, Alexi A. Wright, Christopher J. Sweeney

    Foilsithe / Cruthaithe 2016
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: